Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03817840 · ClinicalTrials.gov registry record
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
A clinical trial of Cushing's Syndrome, sponsored by Columbia University.
- Completed
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT03817840: Completed study of Cushing's Syndrome, sponsored by Columbia University.
NCT03817840 is a study of Cushing's Syndrome that has completed, run by Columbia University. The registered enrollment target is 8 participants, below the 766-participant average among 5 other Cushing's Syndrome trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03817840, a study of Cushing's Syndrome, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease. The objective is to identify the mechanisms that influence both the accumulation of lipodystrophic fat and also the changes in energy expenditure and metabolism that accompany them. The study is designed to determine if the high cortisol and AgRP levels in the blood of people living with Cushing's syndrome, either from taking steroid medications or from tumors, impact body fat and metabolism by turning off brown fat, which is a type of fat that increases one's metabolism.
Primary Outcome
Resting energy expenditure (REE) will be measured by whole room indirect calorimetry prior to and following cure of Cushing's Disease (CD).
Conditions Studied
Interventions
- PROCEDURE Treatment of Cushing's
Study Locations (1)
New York
- Columbia University Neuroendocrine Unit - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2021-07-01 |
What the finished NCT03817840 record still lists
NCT03817840 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 766-participant average among 5 other Cushing's Syndrome trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cushing's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Treatment of Cushing's is the first listed.
NCT03817840 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03817840 about?
NCT03817840 is a clinical study titled "Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease". This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease. The objective is to identify the mechanisms that influence both the accumulation of lipodystrophic fat and also the changes in energy expenditure and...
What is the current status of trial NCT03817840?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2018-07-16. Estimated completion is 2021-07-01.
What conditions does trial NCT03817840 study?
This clinical trial studies the following conditions: Cushing's Syndrome.
What interventions are being tested in trial NCT03817840?
The interventions under investigation include: Treatment of Cushing's (PROCEDURE).
Who is sponsoring clinical trial NCT03817840?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03817840 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
RECRUITING · Phase 2
-
Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
RECRUITING · Phase 2
-
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
COMPLETED
-
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
COMPLETED · Phase 2
-
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI